Hepatitis C virus
hideHepatitis C virus (HCV) is a small (55-65 nm in size), enveloped, positive sense single strand RNA virus in the family Flaviviridae. Although Hepatitis A virus, Hepatitis B virus, and Hepatitis C virus have similar names (because they all cause liver inflammation), these are distinctly different viruses both genetically and clinically.
For more information about Hepatitis C virus, read the full article at
Wikipedia.
This text uses material from Wikipedia and is available under the GNU Free Documentation License.
News tagged with hepatitis c virus
Alarming trend -- antiviral therapy to treat hepatitis C is declining in the US
Nov 24, 2009 |
not rated yet |
0
Researchers from the University of Michigan determined that only 663,000 of the approximately 3.9 million Americans with hepatitis C virus (HCV) infection received antiviral therapy between 2002 and 2007. Treatment rates ...
Multitasking may be Achilles heel for hepatitis C
Nov 23, 2009 |
5 / 5 (1) |
0
(PhysOrg.com) -- Hepatitis C, a formidable virus that affects 130 million people worldwide, is nursing some pretty impressive bruises. By knocking out sections and subsections of one of its proteins, scientists reveal weak ...
Extending treatment after liver transplant may benefit patients with hepatitis C recurrence
Nov 01, 2009 |
not rated yet |
0
Extending hepatitis C treatment for liver transplant patients beyond current practice results in high rates of clearance of the hepatitis C virus from the blood, as well as a low rate of relapse, according to a Henry Ford ...
Is endotoxin receptor CD14 rs2569190/C-159T gene correlated with chronic hepatitis C?
Aug 26, 2009 |
not rated yet |
0
It is still unknown why the natural history of chronic disease caused by hepatitis C virus (HCV), which currently infects 3% of the world's population, varies from mild in some patients to rapidly progressing in others.
Hepatitis C virus channels efforts into cell survival
Aug 17, 2009 |
not rated yet |
0
Researchers at the University of Leeds have discovered a previously unknown mechanism that allows the hepatitis C virus (HCV) to remain in the body for decades.
New strategy for inhibiting virus replication
Aug 14, 2009 |
5 / 5 (1) |
1
Viruses need living cells for replication and production of virus progeny. Thus far, antiviral therapy primarily targets viral factors but often induces therapy resistance. New improved therapies attempt to targets cellular ...
The hepatitis healing power of blueberry leaves
Aug 07, 2009 |
5 / 5 (6) |
0
A chemical found in blueberry leaves has shown a strong effect in blocking the replication of the Hepatitis C virus, opening up a new avenue for treating chronic HCV infections, which affect 200 million people worldwide and ...
Current hepatitis C treatments work equally well, researchers report
Aug 07, 2009 |
not rated yet |
0
The three treatment combinations for clearing the most common form of the hepatitis C virus work equally well with similar side effects, UT Southwestern Medical Center researchers and their colleagues in 13 ...
First human gets new antibody aimed at hepatitis C virus
Aug 06, 2009 |
5 / 5 (3) |
0
Building upon a series of successful preclinical studies, researchers at MassBiologics of the University of Massachusetts Medical School (UMMS) today announced the beginning of a Phase 1 clinical trial, testing the safety ...
Hyperferritinemia is another surrogate marker of advanced liver disease
May 13, 2009 |
not rated yet |
0
High serum ferritin, being a hallmark of hereditary hemochromatosis , is frequently found in chronic hepatitis C, alcoholic or non-alcoholic steatohepatitis and non-alcoholic fatty liver disease patients . A study in Italy ...
Visualizing virus replication in three dimensions
May 07, 2009 |
5 / 5 (1) |
0
Dengue fever is the most common infectious disease transmitted by mosquitoes - some 100 million people around the world are infected. Researchers at the Hygiene Institute at Heidelberg University Hospital ...
Novel antibody prevents infection by hepatitis C virus
May 05, 2009 |
5 / 5 (3) |
0
Taking aim at a leading cause of liver failure in the United States, a team of scientists at the Massachusetts Biologic Laboratories (MBL) of the University of Massachusetts Medical School (UMMS) has developed a human monoclonal ...
Added anti-viral improves response, halves duration of hepatitis C treatment
Apr 30, 2009 |
1 / 5 (1) |
0
The addition of the anti-viral drug telaprevir to a standard treatment for hepatitis C can shorten the duration of therapy and increase the number of patients who can be cured of their disease, according to the results of ...
Mutations within a conservative region of HCV affects the therapy
Mar 30, 2009 |
not rated yet |
0
At least 200 million individuals are currently infected with hepatitis C virus (HCV) worldwide. Approximately 30%-50% of patients respond to interferon/ribavirin combination therapy. Response to interferon therapy depends ...
Two-day results predict ultimate response to therapy in chronic hepatitis C
Mar 20, 2009 |
not rated yet |
0
A new study suggests that previously noted low rates of successful hepatitis C virus (HCV) therapy in African Americans are in large part due to very early differences in the antiviral activity induced by interferon. The ...
- Pages: 1
